New insider activity at PROCEPT BioRobotics ( (PRCT) ) has taken place on August 14, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Frederic Moll has made a significant investment in PROCEPT BioRobotics by purchasing 20,000 shares of the company’s stock. This transaction is valued at $785,000, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on PRCT stock
In the past 24 hours, Procept BioRobotics has experienced significant developments impacting its stock. The company reported strong Q2 2025 earnings, with a 48% revenue increase driven by robust demand for its robotic systems and consumables, particularly in the U.S. market. Despite challenges such as increased operating expenses and continued net loss, the company remains optimistic due to improved gross margins and favorable Medicare updates for its Aquablation therapy. These positive operational achievements have led to an upward revision of the full-year revenue guidance to $325.5 million. However, Piper Sandler lowered the price target for Procept BioRobotics from $80 to $55, citing the company’s Q2 results aligning with preannouncements and the need to set realistic expectations for the incoming CEO. The ongoing clinical study on Aquablation therapy for prostate cancer treatment is also seen as a promising development, potentially increasing investor interest. Overall, the company’s strategic focus on growth and leadership transition under new CEO Larry Wood is expected to bolster its market position.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
The overall stock score of 52 reflects a mix of strong revenue growth and a robust equity position, offset by ongoing profitability and cash flow challenges. Technical indicators suggest a bearish trend, while valuation metrics highlight concerns due to the lack of profitability. Positive sentiment from the earnings call and the appointment of a new CEO provide some optimism for future growth.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
YTD Price Performance: -51.44%
Average Trading Volume: 1,071,286
Technical Sentiment Signal: Sell
Current Market Cap: $2.15B